According to Zhito Finance APP, Bona Biotechnology (06955) is up nearly 9%, as of the time of writing, up 8.92%, priced at 8.3 HKD, with a trading volume of 15.9053 million HKD.

Zhongtai released a research report stating that Bona Biotechnology's biosimilar products are continually accumulating and expanding; revenues for 2021/2022/2023 reached 0.16, 0.52, and 0.62 billion yuan respectively, with the first half of 2024 generating revenue of 0.36 billion yuan. The company's scale effect is becoming evident, with sales expense ratio, management expense ratio, and R&D expense ratio (R&D expenses in 2024 H1 decreased by approximately 40.2 million yuan, mainly due to increased investments in deferred development costs in the second half of 2023 and more R&D projects advancing to Phase III clinical trials for capitalization) in the first half of 2024 at 40.4%, 6.7%, and 23.6%, significantly optimized compared to 2023, leading to the company's first profit in the first half of 2024.

The bank continues to indicate that the company has the capability to push the biosimilar of Dexamethasone into the core markets of Europe and the United States in terms of R&D and production. They plan to establish licensing agreements in the developed markets of Europe, America, and Japan once the international Phase III trials for Dexamethasone are completed, and the company's business expansion into overseas markets is anticipated soon. Considering the company's excellent resources backed by Luye Pharma, the domestic biosimilar market is continually diversifying and expanding. With the European and American markets entering the late stages of clinical research, the innovative drug sector features several differentiated products. Established external licensing agreements have demonstrated the company's BD capabilities.